L E Abrey

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
  2. ncbi A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
    L E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 53:259-65. 2001
  3. doi Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
  4. ncbi Temozolomide for treating brain metastases
    L E Abrey
    Department of Neurology at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 28:34-42. 2001
  5. ncbi Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1145-51. 2007
  6. ncbi Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
    S A Grimm
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1851-5. 2007
  7. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009
  8. ncbi Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
  9. doi Bacterial and fungal meningitis in patients with cancer
    J E Safdieh
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA
    Neurology 70:943-7. 2008
  10. ncbi Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial
    A M Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10021, USA
    J Neurooncol 78:277-80. 2006

Collaborators

Detail Information

Publications11

  1. ncbi Treatment for primary CNS lymphoma: the next step
    L E Abrey
    Departments of Neurology and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3144-50. 2000
    ..The reported protocol was designed to optimize and enhance the chemotherapeutic component of treatment...
  2. ncbi A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
    L E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 53:259-65. 2001
    ..Treatment options for patients with recurrent brain metastases are extremely limited. This study was designed to determine the safety and efficacy of temozolomide in the treatment of recurrent or progressive brain metastases...
  3. doi Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
    S A Grimm
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neurology 71:1355-60. 2008
    ..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement...
  4. ncbi Temozolomide for treating brain metastases
    L E Abrey
    Department of Neurology at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 28:34-42. 2001
    ..017), primarily in patients with newly diagnosed brain and lung metastases...
  5. ncbi Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1145-51. 2007
    ..There is, however, a paucity of research on cognitive functions in this population...
  6. ncbi Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
    S A Grimm
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1851-5. 2007
    ..Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown...
  7. pmc Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
    F M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neurology 73:1200-6. 2009
    ..However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically...
  8. ncbi Cognitive functions in survivors of primary central nervous system lymphoma
    D D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Neurology 62:548-55. 2004
    ..This combined regimen prolongs patient survival, but also carries a substantial risk for delayed neurotoxicity particularly in the elderly. However, cognitive outcome evaluations have not been included in most clinical trials...
  9. doi Bacterial and fungal meningitis in patients with cancer
    J E Safdieh
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA
    Neurology 70:943-7. 2008
    ..To analyze cases of bacterial and fungal meningitis in patients with cancer...
  10. ncbi Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial
    A M Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10021, USA
    J Neurooncol 78:277-80. 2006
    ..Disease was stable in 6 of 18 patients and the median survival was 27 weeks. This regimen was well tolerated and a phase II trial using a dose of 30 mg/m2 of vinorelbine is warranted...
  11. ncbi Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma
    J J Raizer
    Department of Neurology, Feinberg School of Medicine, Northwestern University, Abbott Hall, Room 1123, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    J Neurooncol 71:173-80. 2005
    ..Patients often have complete responses but relapses are common. We characterized the MR spectra of PCNSL patients, correlated MRSI with MRI and evaluated whether early recurrence could be detected by MRSI...